Bulk order Acrobiosystems for Chinese

Chinese

A-Z

SARS-CoV-2 | CD24 | CD73 | Trimer | CD19 | PD-1

There is no goods in the shopping cart !

My Cart

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9

Home
Product & Service

Products by Category

Recombinant proteins and more
FDA DMF Filed ProteinsHot SARS-CoV-2 Related ProductsHot Immune Checkpoint ProteinsHot Targets of CAR-T Cell TherapyNew Biosimilar Drug TargetsHot Anti-idiotypic AntibodyHot Fc Receptor Proteins Llama IgG Fc Fusion ProteinNew Bio-Markers & CD Antigens ActiveMax -Best Cytokines Viral Proteins Enzymes Antibodies All Recombinant Proteins
Services

Innovation Lab ServicesNew SPR /BLI analytical serviceNew

Pre-labeled proteins
Biotinylated protein collectionHot FITC & PE labeled ProteinsNew Fluorescent fusion proteins
Kits
SARS-CoV-2 Related Kit ProductsNew Pre-Coupling Magnetic BeadsNew Universal ELISA KitsNew ELISA Assay Kits for Quantitative Analysis of Therapeutic Antibodies in Serum SamplesNew Inhibitor Screening Kits
Others
HPLC-verified Proteins Integrin - Integrin Proteins BCMA - B-Cell Maturation Antigen TIGIT - TIGIT Signaling Axis

Hot Products

Supports on COVID-19 R&D
Reagents for vaccine developmentNew Reagents for diagnostic developmentNew SARS-CoV-2 related productsNew SARS-CoV-2 related kitsNew
Others
CD19 proteinsHot Anti-FMC63 mAbHot CD3 proteinsHot CD47 proteins CD24 & Siglec-10 proteinsHot CD73 proteinsNew Siglec-15 proteinsHot CD20 proteinsExclusive FGL1 proteinsHot PD1 proteinsHot
Support

How to Order Shipping & Payments Global Distributors Testimonials Download Brochures Download COA
Application

Quantitative Analysis of mAb in Serum Evaluation of CAR Expression
X-LAB
Company

About Us Join Us Contact Us
Activities

News Exhibitions Promotion
COVID-19 R&D ^New

Your Position: Home > Immune Checkpoint Proteins > PD-1 > PD1-HP2F2

PE-Labeled Human PD-1 / PDCD1 Protein, Fc Tag, His Tag (recommended for neutralizing assay)

INTRODUCTION

QC & Assay Protocol

Citation & Background

Synonym
PDCD1,PD1,CD279,SLEB2
Source
PE-Labeled Human PD-1, Fc tag, His tag (recommended for neutralizing assay) (Cat. No. PD1-HP2F2) is produced via conjugation of PE to Human PD-1, Fc tag, His tag under optimal conditions. Human PD-1, Fc tag, His tag is expressed in HEK293 cells containing AA Leu 25 - Gln 167 (Accession # Q15116-1).
Predicted N-terminus: Leu 25
Request for sequence
Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus, followed by a polyhistidine tag.
The protein has a calculated MW of 44.7 kDa.
Application
Flow Cytometry (Neutralizing assay)
Conjugate
PE
Excitation source: 488 nm spectral line, argon-ion laser
Excitation Wavelength: 488 nm
Emission Wavelength: 575 nm

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, 0.5% BSA, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
1. -20^°C to -70^°C for 12 months in lyophilized state;
2. -70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity-FACS

FACS assay shows that recombinant Biotinylated FACS

Flow Cytometry assay shows that PE-Labeled Human PD-1, Fc Tag, His Tag (recommended for neutralizing assay) (Cat. No. PD1-HP2F2) can bind to 293T cells overexpressing human PD-L1. 1 μl stock solution per million cells (QC tested).

Request for protocol

FACS analysis shows that the binding of PE-Labeled Human PD-1, Fc Tag, His Tag (recommended for neutralizing assay) (Cat. No. PD1-HP2F2) to 293T overexpressing PD-L1 was inhibited by increasing concentration of neutralizing anti- human PD-L1 antibody. The IC50 is 0.29 μg/ml (QC tested).

Request for protocol

Background
Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.
References
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Order Details

PD1-HP2F2-50tests

Price(USD) : $300.00

PD1-HP2F2-250tests

Price(USD) : $1050.00

Add to Cart

Bulk Inquiry Customize Product

Find out what kind of services we can provide for this target.

Promotion & Exhibitions

SARS-CoV-2 Proteins and Inhibitor Screening Kit

bioSeedin webinar 17th——《GM-CSF Antibody for the Treatment of CRS in COVID-19》
19th Annual Peptalk

Drug Development Status

Number of Launched Drugs：6 Details
Number of Drugs in Clinical Trials：75 Details
Latest Research Phase：Approved

More Recommended Products

Datasheet & Documentation

Request for DMF

DMF (Drug Master File)

Contact Us

order@acrobiosystems.com

techsupport@acrobiosystems.com

+1 800-810-0816 (US)

+86 400-682-2521 (AP)

Show All Distributors

New Product Launch

Questions & Comments

English Name	Research Code	Research Phase	Company	First Brand Name	First Approved Country	First Indication	First Approved Company	First Approved Date	Indications	Clinical Trials
Prolgolimab	BCD-100	Approved	Biocad						Melanoma	Details
Toripalimab	JS-001; SO-001; TAB-001	Approved	Shanghai Junshi Biosciences, Suzhou Zhonghe	Toripalimab Injection	cfda	Metastatic melanoma		2018-12-17	Hepatocellular carcinoma (HCC), Melanoma	Details
Pembrolizumab	MK-3475; SCH-900475; h409A11,MK3475	Approved	Merck Sharp & Dohme	KEYTRUDA	fda	Non small cell lung cancer (NSCLC), Metastatic melanoma, Head and neck cancer, Advanced melanoma	MERCK SHARP DOHME	2014-09-04	Gastric cancer, Colorectal neoplasms, Advanced renal cell carcinoma (RCC), Primary mediastinal B cell lymphoma, Urothelial cancer, Solid tumours, Squamous cell carcinoma of head and neck cancer (SCCHN), Hepatocellular carcinoma (HCC), Microsatellite instability-high cancer, Advanced melanoma, Head and neck cancer, Hodgkin lymphoma, Small cell lung cancer (SCLC), Non small cell lung cancer (NSCLC), Diffuse large B cell lymphoma, Merkel cell carcinoma, Metastatic melanoma, Cervical carcinoma, Melanoma	Details
Nivolumab	MDX-1106; BMS-936558; BMS-936558-01; ONO-4538; ono-0123,MDX1106,BMS936558,ONO4538	Approved	Ono Pharmaceutical, Bristol-Myers Squibb	Nivolumab	日本	Metastatic melanoma	小野制药	2014-07-04 00:00:00.0	Gastric cancer, Advanced renal cell carcinoma (RCC), Urothelial cancer, Squamous cell carcinoma of head and neck cancer (SCCHN), Hepatocellular carcinoma (HCC), Head and neck cancer, Hodgkin lymphoma, Urogenital cancer, Non small cell lung cancer (NSCLC), Renal cell carcinoma, Colorectal cancer, Metastatic melanoma, Metastatic colorectal cancer (CRC), Renal carcinoma, Melanoma	Details
Sintilimab	IBI-308	Approved	Innovent Biologics, Lilly	Sintilimab Injection	cfda	Hodgkin lymphoma		2018-12-24	Hodgkin lymphoma	Details
Cemiplimab	REGN-2810; SAR-439684	Approved	Regeneron Pharmaceutical, Sanofi	LIBTAYO	fda		REGENERON PHARMACEUTICALS	2018-09-28	Squamous cell cancer	Details
Tislelizumab	BGB-A317	Approved	BeiGene, Celgene, Boehringer Ingelheim	Tislelizumab Injection	cfda	Hodgkin lymphoma, Urothelial cancer		2019-12-26	Urothelial cancer, Hodgkin lymphoma	Details
Camrelizumab	HR-301210; INCSHR-1210; SHR-1210,HR301210; INCSHR1210; SHR1210	Approved	Jiangsu Hengrui Medicine, Suzhou Shengdiya	Camrelizumab for Injection	cfda	Advanced solid tumors, Hepatocellular carcinoma (HCC), Hodgkin lymphoma, Esophageal squamous cell carcinoma		2019-05-29	Esophageal squamous cell carcinoma, Advanced solid tumors, Hepatocellular carcinoma (HCC), Hodgkin lymphoma	Details

English Name	Research Code	Research Phase	Company	Indications	Clinical Trials
Spartalizumab	PDR-001	Phase Ⅲ	Novartis	Melanoma	Details
INSIX RA (Indus Biotech)		Phase Not Specified	Indus Biotech Private Limited	Inflammation, Rheumatoid arthritis (RA)	Details
Pidilizumab	CT-011; MDV-9300	Phase Ⅱ		Glioma, Diffuse large B cell lymphoma, Prostate cancer, Follicular lymphoma, Multiple myeloma (MM), Colorectal cancer, Acute myeloid Leukemia (AML), Hepatocellular carcinoma (HCC), Renal carcinoma, HCV infection, Pancreatic cancer, Melanoma	Details
CS-1003	CS-1003	Phase Ⅲ	CStone Pharmaceuticals	Hepatocellular carcinoma (HCC)	Details
BI-754091	BI-754091	Phase Ⅱ	Boehringer Ingelheim	Solid tumours	Details
Cetrelimab	JNJ-63723283; JNJ-3283	Phase Ⅲ	Johnson & Johnson	Multiple myeloma (MM)	Details
iPD1 CD19 eCAR-T therapy (Marino Biotechnology)		Phase Ⅰ	Marino Biotechnology, Chengdu Galaxy Biomed, Peking University	B-cell lymphoma	Details
AK-104	AK-104,AK104	Phase Ⅱ	Akeso Biopharma	Solid tumours	Details
PD-1 knockout EBV-CTL (Nanjing Medical University)		Phase Ⅱ	Nanjing Medical University	Nasopharyngeal cancer, Gastric cancer, Diffuse large B cell lymphoma, Lymphoma, Hodgkin lymphoma	Details
Genolimzumab	CBT-501; GB-226	Phase Ⅱ	Genor Biopharma, CBT	Thymic tumor, Solid tumours, Soft tissue sarcoma, Hepatocellular carcinoma (HCC), Peripheral T cell lymphoma (PTCL), Non-Hodgkin B-cell lymphomas, Cervical carcinoma	Details
AK-112	AK-112,AK112	Phase Ⅰ	Akeso Biopharma	Malignancies	Details
TY-101	TY-101,TY101	Phase Ⅱ	大有生物	Solid tumours, Lymphoma	Details
MAX-10181	MAX-10181	Phase Ⅰ	Maxinovel Pharmaceuticals	Solid tumours	Details
BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army)		Phase Ⅱ	General Hospital of the People's Liberation Army	Multiple myeloma (MM)	Details
GS-4224	GS-4224	Phase Ⅱ	Gilead Sciences	Solid tumours	Details
609-A (SBio)	609-A	Phase Ⅰ	3SBio	Solid tumours	Details
CA-170	CA-170; AUPM-170	Phase Ⅱ	Aurigene, Curis	Cancer	Details
Nivolumab/Relatlimab	BMS-936558/BMS-986016; BMS-986213	Phase Ⅲ	Bristol-Myers Squibb	Melanoma	Details
REMD-288	REMD-288	Preclinical	REMD Biotherapeutics, Buchang Pharma	Cancer	Details
LY-3434172	LY-3434172	Phase Ⅰ	Lilly	Solid tumours	Details
INCB-086550	INCB-086550	Phase Ⅰ	Incyte	Solid tumours	Details
Dostarlimab	ANB-011; TSR-042; WBP-285	BLA Filing	AnaptysBio, Tesaro, GlaxoSmithKline	Fallopian tube cancer, Endometrial cancer, Peritoneum cancer, Ovarian cancer	Details
AK-105	AK-105,AK105; AK 105	BLA Filing	Akeso Biopharma	Metastatic non-small cell lung cancer, Nasopharyngitis, Solid tumours, Hepatocellular carcinoma (HCC), Hodgkin lymphoma	Details
Recombinant humanized anti-PD-1 monoclonal antibody(Akeso Biopharma)	AK-103; HX-008	Phase Ⅲ	Akeso Biopharma, Taizhou Hanzhong Biomed, Hansi Biological Pharmaceutical	Gastroesophageal junction adenocarcinoma	Details
MiHA-loaded PD-L silenced DC vaccination (Radboud University)		Phase Ⅱ	Radboud University	Multiple myeloma (MM), Acute myeloid Leukemia (AML), Non-Hodgkin's lymphoma (NHL), Chronic myeloid leukemia (CML )	Details
AMP-224	AMP-224; AMP-244; GSK-2661380	Phase Ⅰ	Amplimmune, MedImmune, National Cancer Institute, GlaxoSmithKline	Solid tumours, Colorectal cancer	Details
Balstilimab	AGEN2034; RebmAb-700	Phase Ⅱ	Agenus, Ludwig Institute for Cancer Research	Solid tumours, Cervical carcinoma	Details
RG-6084	RG-6084	Phase Ⅰ	Roche	HBV infection	Details
Retifanlimab	INCMGA-0012; INCMGA-00012; MGA-012	Phase Ⅲ	MacroGenics, Incyte, Zai Lab	Gastric cancer, oesophageal cancer	Details
BCD-217	BCD-217	Phase Ⅱ	Biocad	Melanoma	Details
SL-279252	SL-279252; TAK-252	Phase Ⅰ	Shattuck Labs	Gastric adenocarcinoma, Non small cell lung cancer (NSCLC), Diffuse large B cell lymphoma, Renal cell carcinoma, Urothelial cancer, Solid tumours, Squamous cell carcinoma of head and neck cancer (SCCHN), Hodgkin lymphoma, Gastroesophageal junction adenocarcinoma, Melanoma	Details
T3011疱疹病毒（深圳市亦诺微医药）		Phase Ⅰ		Solid tumours	Details
CD19-PD1-CAR T cell therapy (Chinese PLA General Hospital)		Phase Ⅱ	General Hospital of the People's Liberation Army	B-cell lymphoma	Details
Recombinant human anti-PD-1 monoclonal antibody(Sumgen)	SG-001	Phase Ⅰ	Hangzhou sumgen biotechnology	Solid tumours	Details
Multiple target antigen stimulating cell therapy (HengRui YuanZheng Biotechnology)		Phase Ⅱ	HengRui YuanZheng Biotechnology	Solid tumours	Details
MEDI-0680	AMP-514; MEDI-0680,AMP514; MEDI0680	Phase Ⅱ	MedImmune	B-cell lymphoma	Details
Sym-021	Sym-021,Sym 021; Sym021	Phase Ⅰ	Symphogen	Solid tumours, Lymphoma	Details
Recombinant humanized anti-PD-1 monoclonal antibody (Shandong Xinshidai Pharmaceutical)		Phase Ⅰ	Shandong Xinshidai Pharmaceutical	Solid tumours	Details
Programmed cell death 1 antibody (Sun Yat-sen University)		Phase Ⅱ	Sun Yat-sen University	Hepatocellular carcinoma (HCC)	Details
STW204单抗	STW-204	Phase Ⅰ	Stainwei	Solid tumours	Details
Millamolecule		Phase Ⅰ	Bristol-Myers Squibb	Immunological disorders	Details
RO-7121661	RG-7769; RO-7121661	Phase Ⅱ	Roche	Non small cell lung cancer (NSCLC), Solid tumours, Melanoma	Details
XmAb20717	XmAb-20717,XmAb 20717	Phase Ⅰ	Xencor	Solid tumours	Details
CC-90006	C-90006; CC-90006	Phase Ⅰ	AnaptysBio, Celgene	Autoimmune diseases, Psoriasis	Details
YBL-006	YBL-006	Phase Ⅰ	Y Biologics	Advanced solid tumors	Details
ONO-4685	ONO-4685	Phase Ⅰ	Merus, Ono Pharmaceutical	Autoimmune diseases	Details
EBV-Specific TCR-T Cell therapy (Xinqiao Hospital of Chongqing)		Phase Ⅱ	Chongqing Xinqiao Hospital	Squamous cell carcinoma of head and neck cancer (SCCHN)	Details
Recombinant humanized anti-PD-1 monoclonal antibody (Bio-Thera)	BAT-1306,BAT1306	Phase Ⅱ	Bio-Thera Solutions	Gastric cancer, Colorectal neoplasms, Solid tumours, Liver cancer	Details
Recombinant humanized anti-PD-1 monoclonal antibody (Anhui Anke Biotechnology)		Phase Ⅰ	Anke Biotechnology	Triple negative breast cancer, Esophagus cancer, Urothelial cancer, Lung cancer, Lymphoma	Details
HLX-10	HLX-10	Phase Ⅲ	Shanghai Henlius Biotech	Small cell lung cancer (SCLC), Non small cell lung cancer (NSCLC), oesophageal cancer, Squamous cell carcinoma of head and neck cancer (SCCHN), Solid tumours, Liver cancer	Details
MGD-019 (MacroGenics)	MGD-019	Phase Ⅰ	MacroGenics	Solid tumours	Details
IBI318	IBI-318	Phase Ⅰ	Innovent Biologics, Lilly	hematological malignancies, Malignancies	Details
Recombinant humanized anti-PD-1 monoclonal antibody (Sinocelltech)	SCT-I10A	Phase Ⅲ	Sinocelltech	Squamous cell carcinoma of head and neck cancer (SCCHN)	Details
Sasanlimab	PF-06801591; PF-6801591; RN-888	Phase Ⅲ	Pfizer	Bladder cancer	Details
Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute)		Phase Ⅱ	Shanghai Cell Therapy Research Institute	Solid tumours	Details
CS-17938	CS17938	Preclinical	ChipScreen	Immunological disorders, Cancer	Details
IBI315	IBI-315; IBI315	Phase Ⅰ	Innovent Biologics, Hanmi	Cancer	Details
RB-0004	RB-0004,RB0004; RB 0004	Phase Ⅰ	Reyoung Pharmaceutical	Malignancies	Details
Recombinant human anti-PD-1 monoclonal antibody(Yiyi Health Technology)		Phase Ⅰ	Yiyi Health Technology	Malignancies	Details
Recombinant humanized anti-PD-1 monoclonal antibody (Shanghai CP Guojian)		Phase Ⅰ	Shanghai CP Guojian	Solid tumours	Details
JTX-4014 (Jounce Therapeutics)	JTX-4014	Phase Ⅰ	Jounce Therapeutics	Cancer	Details
PD-1 knockout engineered T cells (Anhui Kedgene Biotechnology)		Phase Ⅱ	Anhui Kedgene Biotechnology, Hangzhou Cancer Hospital	Esophagus cancer	Details
IMU-201	IMU-201,PD1-Vaxx	Phase Ⅰ	Imugene	Non small cell lung cancer (NSCLC)	Details
CMAB-819	CMAB8-19,CMAB819; CMAB8 19	Phase Ⅰ	SinoMab Bioscience Ltd, Taizhou Mabtech	Non small cell lung cancer (NSCLC), Hepatocellular carcinoma (HCC)	Details
CX-188		IND Filing	CytomX Therapeutics	Cancer	Details
PD-1 knockout engineered T cells (Cell Biotech)		Phase Ⅰ	Cell Biotech	Renal cell carcinoma, Prostate cancer, Bladder cancer	Details
PD-1 knockout engineered T cells (Chengdu MedGenCell)		Phase Ⅱ	Chengdu MedGenCell, West China Hospital Sichuan University	Lung cancer, Melanoma	Details
Zimberelimab	AB-122; GLS-010; WBP-3055	BLA Filing	Gloria Pharmaceuticals, WuXi AppTec, Arcus Biosciences	Triple negative breast cancer, Gastric cancer, Solid tumours, Liver cancer, Hodgkin lymphoma	Details
MEDI-5752	MEDI-5752	Phase Ⅰ	MedImmune	Solid tumours	Details
MGD-013	MGD-013; PD-1 X LAG-3	Phase Ⅲ	MacroGenics, Zai Lab	Gastric cancer, oesophageal cancer	Details
Recombinant human PD-1 antibody herpes simplex virus		Phase Ⅰ	Yangshengtang Co, Xiamen University	Cancer	Details
HX-009	HX-009,HX009	Phase Ⅰ	Hansi Biological Pharmaceutical, Wuhan Hanxiong Biotechnology Co., Ltd.	Gastric cancer, Colorectal neoplasms, Liver cancer	Details
dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics)	ICTCAR-014	Phase Ⅱ	Innovative Cellular Therapeutics	Non-Hodgkin's lymphoma (NHL)	Details
RO-7247669	RO-7247669	Phase Ⅰ	Roche	Solid tumours	Details
Budigalimab	ABBV-181	Phase Ⅰ	Abbvie	Non small cell lung cancer (NSCLC), Solid tumours, Colorectal cancer, Ovarian cancer	Details
LZM-009	LZM-009,LZM009	Phase Ⅰ	Livzon Group Livzon Pharmaceutical Factory	Solid tumours	Details
Recombinant humanized anti-PD-1 monoclonal antibody (Shanxi Wichida Bright Pharmaceutical)		IND Filing	Shanxi Wichida Bright Pharmaceutical	Unspecified	Details